Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 06BRASILIA2606, BRAZIL - REGULATORY AGENCY FORGING AHEAD WITH NEW

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #06BRASILIA2606.
Reference ID Created Released Classification Origin
06BRASILIA2606 2006-12-14 18:41 2011-07-11 00:00 UNCLASSIFIED//FOR OFFICIAL USE ONLY Embassy Brasilia
VZCZCXRO5250
RR RUEHRG
DE RUEHBR #2606/01 3481841
ZNR UUUUU ZZH
R 141841Z DEC 06
FM AMEMBASSY BRASILIA
TO RUEHC/SECSTATE WASHDC 7650
INFO RUEHRI/AMCONSUL RIO DE JANEIRO 3554
RUEHRG/AMCONSUL RECIFE 6019
RUEHSO/AMCONSUL SAO PAULO 8864
RUEHBU/AMEMBASSY BUENOS AIRES 4478
RUEHAC/AMEMBASSY ASUNCION 5845
RUEHMN/AMEMBASSY MONTEVIDEO 6653
RUCPDOC/USDOC WASHDC
UNCLAS SECTION 01 OF 02 BRASILIA 002606 
 
SIPDIS 
 
SENSITIVE 
SIPDIS 
 
STATE PASS USTR:SCRONIN/MSULLIVAN 
USDOC FOR 3134/USFCS/OIO/WH/SHUPKA 
USDOC FOR 4332/ITA/MAC/WH/OLAC/JANDERSEN/ADRISCOLL/MWAR D 
STATE FOR EB/TPP/BTA and WHA 
 
E.O. 12958:  N/A 
TAGS: ETRD ECON BR
SUBJECT: BRAZIL - REGULATORY AGENCY FORGING AHEAD WITH NEW 
REQUIREMENTS FOR MEDICAL DEVICE REGISTRATION 
 
REF: BRASILIA 2589 
 
1.  (SBU) Summary:  Emboffs met December 12 with representatives of 
Brazil's National Sanitary Vigilance Agency (ANVISA, an FDA-like 
agency) to clarify the scope of new requirements for commercial and 
pricing information for approval of medical device sales and urge 
that the GoB take into account industry concerns over the 
implementation of the measure (reftel).  Economic and Regulatory 
Issues Department Director Pedro Bernardo and International 
Relations Director Rogerio Ferreira argued that the new regulation 
was merely the application to medical devices of the requirements 
for provision of commercial information as part of the ANVISA 
licensing process that were introduced in 2003 by law 10742; these 
requirements already applied to pharmaceuticals.  Bernardo stated 
that both the new regulations and law 10742 only require provision 
of pricing data for licensing approval and do not give ANVISA any 
power over these pricing decisions.  Bernardo stated that the 
regulations apply equally to Brazilian and imported products.  He 
dismissed industry concerns that anti-trust considerations might 
prohibit provision of pricing data.  Bernardo assured Emboffs that 
ANVISA would protect companies' proprietary commercial strategy 
information, but would share with other GoB agencies the pricing 
information provided.  End Summary. 
 
2. (U) Emboffs met, at our request, with ANVISA reps Bernardo and 
Ferreira to urge that industry concerns over a new regulation 
(185/2006) be taken into account, as well as to clarify the 
regulation's provisions.  In order to obtain ANVISA approval for 
registering or re-registering medical devices, the new regulation 
requires companies to provide commercial/pricing data on the 
product.  Companies are required to provide 1) the intended price 
for the product on the Brazilian market; 2) the company's estimates 
of the number of patients that would use the product; 3) factory 
price and distribution margins; 4) expected sales and marketing 
expenses; 5) a list of substitute or similar products and their 
prices; and, 6) if the product is sold in any of ten specified 
countries (Portugal, France, U.S., Germany, Australia, Canada, 
Spain, Italy, Japan and the United Kingdom) then price at which it 
sold in those markets must be submitted, along with supporting 
documentation. 
 
3. (U) Bernardo argued that the new regulation was simply the next 
step in the process of regulating law 10742 of 2003.  This law, he 
said, requires that commercial and pricing data be provided in order 
to register pharmaceuticals and medical devices.  ANVISA began the 
process by requiring the same information for pharmaceuticals, 
which, he affirmed, the companies had been providing without 
incident.  It simply took ANVISA some time to grapple with how to 
approach the less standardized medical devices sector.  Bernardo 
said ANVISA and the Ministry of Health had held extensive 
discussions with government institutions, health insurance companies 
and the industry to understand the market of medical devices. 
After talking to industry and government, in December 2005, ANVISA 
put the resolution 185/2006 for public comment until February 2006. 
In November 2006 the resolution was passed and it goes into effect 
on December 13. 
 
4. (U) According to Bernardo, ANVISA consultations with other 
institutions pointed up a number of information problems in the 
sector.  The federal agencies responsible for the federal health 
system (SUS) and private health insurance companies stated that the 
costs of medical devices have been a large factor in increasing the 
costs of their operations.  There also was considerable confusion 
over pricing of devices and which devices are substitutes, Bernardo 
affirmed.  He alleged that they found in one case that the same 
basic product has sixty different prices on the market from 
different providers. 
 
5. (U) ANVISA and Ministry of Health decided to apply the pricing 
data requirements to about 5 percent of the medical devices on the 
market, according to Bernardo.  The products chosen are the ones 
that have shown consistent price increases over the last five years 
for SUS and health insurers.  Health insurers and government are 
responsible for 80 percent of the demand for these products, 
Bernardo stated. ANVISA stated that current information is 
asymmetric, making it difficult for customs and ANVISA to classify 
products.  Government also faces difficulties in correctly taxing 
these products, Bernardo alleged.  The products listed are for: 
cardiovascular procedures; orthopedic procedures; clinical analysis 
 
BRASILIA 00002606  002 OF 002 
 
 
(laboratory procedures); kidney therapy; ophthalmological 
procedures; hemotherapy procedures; and otorhinolaryngologist 
procedures. 
 
6. (U) Bernardo stated that ANVISA will use the information received 
to put together a database and create a standards nomenclature to 
simplify the process of customs processing and product registration 
with ANVISA.  Government will also use the information to correctly 
tax the products.  ANVISA will also use the information collected to 
provide price and quality comparisons, allowing government bodies 
responsible for procurement to make better decisions.  Bernardo 
affirmed that pricing information is public information and will be 
released to entities with access to its database, but companies' 
proprietary marketing strategy information would be kept 
confidential. 
 
SIPDIS 
 
7. (SBU) Emboffs raised a series of concerns that industry has put 
forward about the measure, including: 1) the difficulty of gathering 
much of the information requested; 2) anti-trust considerations as 
the regulation requires companies to provide pricing data on 
competing products; 3) that the regulation would serve as an 
additional obstacle to getting devices licensed, and thus would 
reduce Brazilian consumers' access to the latest innovative 
technologies; 4) the impression that this regulation creates that 
Brazil is headed towards price controls for these devices; and, 5) 
whether the regulation applies equally to imported and domestic 
devices. 
 
8. (SBU) In dismissing concerns over anti-trust law or that industry 
would have difficulty providing the data, Bernardo argued that the 
pharmaceutical industry has been providing similar data without 
incident for over a year.  The new requirements were not onerous, he 
affirmed, and thus would not limit new product registrations. 
Moreover, the law upon which the new regulation is based does not 
allow for price controls on medical devices.  It would take new 
legislation passed by Congress to introduce such controls.  Finally, 
the regulation applies equally to imported and domestic products, so 
there is no national treatment issue, Bernardo affirmed. 
 
9. (SBU) Emboffs requested an advance copy of the form that 
companies will have to fill out.  The form is now also available on 
the ANVISA internet site (www.anvisa.gov.br), along with an 
instruction manual explaining how to fill out the form.  Companies 
may be required to submit supporting documentation in some cases. 
After the resolution goes into effect on December 13, there will be 
a sixty-day phase in period for companies to begin complying with 
the resolution.  Bernardo implied that, were there clearly serious 
and justified difficulties in meeting the new requirements during 
this period, ANVISA might tweak the procedures or requirements.  But 
it would be forging ahead with implementation, he said. 
 
10 (SBU) Comment:  In our own review of the text of law 10742, upon 
which Bernardo said this measure was based, we did not find specific 
mention medical devices (as opposed to pharmaceuticals).  That does 
not necessarily mean that the new regulation is without legal basis 
in other legislation.  It does suggest, however, that ANVISA's 
ultimate intent is controlling costs in the public health system, as 
law 10742 was clearly aimed at reducing pharmaceutical prices. 
 
SOBEL